Preparing for Potential Covid-19 Vaccine Launch, Says Moderna CEO

The EU deal will not only provide Sanofi and GSK's shot to the region's member nations but will also free the bloc to divert some of those doses to low- and middle-income countries, the drugmakers said.

As reported, Murashko said that the symptoms after being injected with the Russian COVID-19 vaccine "level off" by the next day and the complications are "described in the instructions and are predictable".

"We will soon sign more similar agreements and put together a diverse range of possible vaccines based on different types of technologies", the European Union presidency Ursula von der Leyen said according to the press release.

The Sputnik V COVID-19 vaccine has been developed by Moscow's Gamaleya Research Institute of Epidemiology and Microbiology and it was touted as the "World's first Coronavirus vaccine" when it received approval for public use in August. The Sputnik V is among several vaccine candidates being considered by Indian authorities for the country.

In August, the Commission paid AstraZeneca €336 million to secure under these conditions 300 million doses of its vaccine under development with an option to buy other 100 million shots.

Moderna revealed that the Phase-3 study of its Covid vaccine candidate, mRNA-1273, involving 30,000 volunteers in the United States, has enrolled 25,296 participants as of September 16. The companies aim to have the vaccine available by the second half of 2021. It will be coupled with an adjuvant, a substance that acts as a booster to the vaccine, made by GSK.

He also stated that the vaccine does not provide life-long immunity against the COVID-19 virus, but the vaccination can be repeated as needed.

The companies started a Phase 1/ 2 study in September, followed by a Phase 3 study by the end of 2020. The regulatory processes will be flexible but remain robust.

The Drugs Controller General of India (DCGI) had on September 11 directed the SII to suspend any new recruitment in the phase-II and III clinical trial of the vaccine till further orders after AstraZeneca paused the trials in other countries because of "an unexplained illness" in a participant in the study.

In return for the right to the doses, the European Commission will finance part of the upfront costs faced by vaccine producers. But the Russian government has approved the vaccine which made it the first vaccine to be cleared from human use anywhere in the world. "The end of the year target for getting vaccine roll-out, it's a possibility but there's absolutely no certainty about that because we need three things to happen", Sarah Gilbert earlier told.

Related Articles